Hot Investor Mandate: Leading Biopharmaceutical Seeks Licensing and Collaboration Opportunities For China and Global Market in Oncology, CNS, Autoimmune Disease, and More

20 Oct

One of the leading fully integrated biopharmaceutical companies in China has established three integrated R&D centers, with locations in USA and China. The firm has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes. The firm is actively seeking for licensing/collaboration on development candidates with first-in-class or best-in-class potentials, and commercial products with substantial market opportunities in China and worldwide.

The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease, as well as a technology platform in Cell Therapy.

The firm is looking for companies with capacity and experience in implementing R&D plans. The firm is interested in assets from the US, Europe or other countries, and intends to introduce the product to the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: